Multifactorial mechanisms relate chemotherapy to nausea and vomiting. There is evidence that complex brainstem and neocortical neuronal reflex systems partly under neurohumoral influences mediate nausea and vomiting (Jenkins & Lahay. 1971; Fredrikson et al., 1992; Hursti et al., 1993) . A functional area in the lateral reticular formation at about the level of the olivary nuclei of the medulla oblongata has been termed 'the vomiting centre'. Anatomically, it probably consists of the area postrema and the nucleus of the tractus solitarius and their projections to the parabrachial nuclei and the hypothalamus (Leslie & Reynolds, 1993) . Apart from regulating retching and vomiting, this functional system is held to mediate changes in autonomic activity such as salivation. cutaneous vasoconstriction, pupillary dilatation, gastric acid secretion and gut motility. The functional 'centre' is activated by a coordinating system involving a variety of anatomical organs and systems (Borison. 1974 (Borison. , 1981 . Neuropathways from the limbic system and the cerebrum may be involved, and 'the vomiting centre' also receives input from neocortical areas, the vestibular system, the gastrointestinal tract, the gut and the spinal nerves.
The chemoreceptor trigger zone, a structure in or near the area postrema. located bilaterally on the floor of the fourth ventricle. is also functionally involved in emesis. The blood-brain barrier does not operate in this area (Borison, 1974 (Borison, . 1981 ) and the structure is exposed to cerebrospinal fluid as well as circulating blood. Neurons from the chemoreceptor trigger zone project to the inside of the blood-brain barrier. The chemoreceptor trigger zone has been implicated as a sensor of chemotherapeutic agents, and its sensitivity may be modulated by circulating hormones.
Catecholamines have been suggested to have a role in the neurohumoral control of nausea and vomiting since they may sensitise the area postrema to emetogenic substances (Leslie & Reynolds. 1993; Andrews et al.. 1988) . The area postrema contains a-adrenergic reeceptors (Beleslin, 1992) , and noradrenaline is found in high concentrations in this region (Leslie & Reynolds, 1993) . m.-Adrenoreceptors subserving emesis have also been located in the nucleus of the tractus solitanrus (Beleslin. 1992) . Drugs that act on central aadrenergic receptors produce emesis (Jenkins & Lahay, 1971; Borison, 1989) . In cats, for example. there is a profound emetic response to noradrenaline infusion that is abolished by blockade of a.-adrenoceptors (Beleslin & Strbac. 1987 alcoholic beverages, bananas and products containing vanilla from the evening prior to chemotherapy until chemotherapy completion. The night before the start of the second chemotherapy cycle. the urinary sample was collected in a plastic container with sodium sulphite as antioxidant and included the volume from the time of voiding before going to bed until the time of rising (typically between 06.00 and 07.30 h). Volume and collection time were noted. The specimens were acidified with 2 N hydrochloric acid to pH 3 and stored at -18'C until analysed for adrenaline and noradrenaline. All samples were analysed by high-performance liquid chromatography (Riggin & Kissinger. 1977; Hjemdahl et al., 1989) . Excretion rate was expressed in pmol min-'. Nausea and vomiting Similar but not identical nausea rating procedures were undertaken in cohorts 1 and 2. On the day of their second chemotherapy course all patients rated nausea on a 100 mm visual analogue scale (VAS). A zero score is anchored at the left end with 'no nausea at all' and a maximum score of 100 denotes 'worst possible nausea'. Selfreports of nausea (VAS) and vomiting were given during (one report) and after (two reports) infusion on the treatment day. Patients also reported their nausea and vomiting every 6 h for the following 2 days.
Since patients in cohort 2 received a more emetogenic therapy than patients in cohort 1, a median split approach was adopted to relate nausea and vomiting to catecholamine excretion separately for each cohort. On the first and second day after chemotherapy, patients in cohort 1 continued to rate their nausea on a visual analogue scale and the median split approach was adopted to define the 'high' and 'low' nausea groups. During the same period, patients in cohort 2 rated their nausea using four categories: no. mild, moderate and severe nausea. No and mild nausea were grouped to form the group with 'low' nausea, while moderate and severe nausea were grouped to form the group with 'high' nausea. Therefore, the distribution of patients is not symmetrical in the 'low' and 'high' nausea groups. Emetic episodes were counted by the patients during the chemotherapy day and over the first and second days after chemotherapy.
Statistical analyses Medians were calculated separately for each group. and those with relatively lower values were grouped separately to form groups 'low' in nausea or catecholamine excretion, while those with relatively higher values formed groups 'high' in nausea or catecholamine excretion. To increase the statistical power groups were combined in the statistical analyses. Data were analysed by the ' test and Student's t-test. Relative risks and confidence intervals were also calculated (see Hursti et al., 1992) .
Results

Rating methods
On the chemotherapy day cohort 2 performed both category and VAS ratings. making it possible to compare the covariation between the two methods. The two rating methods were highly correlated V(1) = 22.24; P<0.0001], indicating that they should result in similar grouping.
Cathecolamine excretion
The medians used to form groups 'low' and 'high' in adrenaline excretion were 7.0 and 4.8 pmol min-' for cohorts 1 and 2 respectively. Corresponding numbers for noradrenaline were 76.1 and 82.7 pmol min-'. Average noradrenaline excretion was similar in cohorts 1 and 2. being 96.4 and 88.6 pmol min -' respectively. Adrenaline excretion was similar in the two cohorts, being 7.4 and 5.3 pmol min' respectively. Neither difference was statistically significant [t <(61) <1.84; NS]. There was no apparent circadian variation in catecholamine excretion since early and late risers, as defined by median split, had similar rates for both catecholamines (t < 1; NS). Among the patients with 'high' noradrenaline excretion, 18 had 'high' and 13 had 'low' excretion of adrenaline, whereas among patients with 'low' adrenaline excretion 18 showed 'low' and 13 'high' noradrenaline excretion. Thus, excretion of the two catecholamines did not covary significantly [X2(l) = 1.61; NS].
Pattern of nausea and vomiting
Reflecting the effect of cisplatinum treatment, mean VAS ratings of nausea were higher during the treatment day in cohort 2 41.2. s.d. 26.4i than cohort 1 (8.9. s.d. 14.8).
[t (60) = 5.10: P<0.0001]. The patients in cohort 1 did not experience any-Vomiting. except for one patient >-ho had a single episode on the chemotherapy day. Therefore the association betwxeen catecholamines and Xomitingz was analy sed for the patients in cohort 2 only. .Adrenaline >-as not consistently related to nausea since all f tests wxere non-significant (Figure lb) .
Twenty-six patients reported vromiting (Table lI>. but this xwas not associated wxith catecholamine excretion.
Discussion
Pretreatment night-time noradrenaline excretion predicted delayed chemotherapy-induced nausea. There are species differences in emetic activity of catecholamines (Samardzic & Beleslin. 1989) . The findings of the present study indicate that noradrenaline as compared with adrenaline is more closelv linked to emesis in humans. High levels of endogenous noradrenaline auzment the intensity of delayed chemotherapy-induced nausea. The mechanism may be central or peripheral in origin. We have previously demonstrated that cortisol excretion is inversely related to the intensity of nausea resultinz from chemotherapy. We (Fredrikson et al.. 25 25 -1992 : Hursti et al.. 1993 sugzested that the anti-inflammatorv effect of cortisol could have antiemetic properties bv preventing the release of serotonin in the gut or by sensitising peripheral receptors involved in the action of antiemetic drugs (Sagar. 1991) . In addition. it is possible that cortisol affects the blood-brain barrier permeabilitv to limit influx of toxic substances to the central nervous svstem (CNS). Corticosteroids may also potentiate the antiemetic effects of. for example. ondansetron by sensitising receptors in the CNNS (Sagar. 1991) . It might be speculated that noradrenaline. in contrast to cortisol (Fredrikson et al.. 1992 : Hursti et al.. 1993 . could promote the release of serotonin in the gut or alternatively affect 5HT-receptor sensitivity. It is also conceivable that high levels of noradrenaline are associated u-ith receptor sensitivity in the CN S. In addition. adrenergic activitv could facilitate the area postrema to circulating emetozenic substances. This is in line with the suvzestion that o-adrenergicallv mediated sensitisation of the area postrema during chemotherapy treatment may result in enhanced nausea (Borison. 1974 (Borison. . 1981 . The fact that noradrenaline as compared u-ith adrenaline Auas more closely related to nausea in our study may implicate a CNS orinin of the obtained .0 E z 1 C effect. since noradrenaline. but not adrenaline, is found in high concentrations in the area postrema (Leslie & Reynolds, 1993) . This may explain why high levels of circulating noradrenaline but not adrenaline were related to nausea in our study. Thus. it is possible that noradrenaline sensitises the area postrema to toxic substances more than does adrenaline.
It has also been argued that peripheral and central noradrenaline are correlated (Svensson, 1987) . During conditions of stress there are parallel changes in peripheral sympathetic activity and in the locus coeruleus in the brain, the network of which accounts for most of the brain noradrenaline (Svensson, 1987) . Locus coeruleus activity is influenced by both external sensory and internal vegetative events (Svensson, 1987) , and the hypothesis has been advanced that a high activity facilitates performance of the gastrointestinal system (Elam et al., 1986) . Since locus coeruleus activation is an integrated part of the anxiety response, this brain structure may be the final common pathway that mediates the wellknown (Andrykowski et al., 1985) relationship between anxiety and nausea.
Delayed as compared with acute nausea was more strongly related to adrenergic activity. Since the nausea intensity was similar during acute and delayed nausea, it is not likely that individual modulating factors are of less importance only because nausea is more severe during chemotherapy. Instead. data may indicate that factors associated with adrenergic activation are prognostic specifically for delayed nausea.
It has been demonstrated that exogenous administration of catecholamines results in improved conditionability in animals (Weinberger et al., 1984) . Thus, to the extent that delayed nausea in part reflects conditioned nausea even in the second cycle of chemotherapy (Morrow, 1982; Andrykowski et al.. 1985; Burish & Carey, 1986 . the data of the present study may also indicate that noradrenaline facilitates conditioning of nausea. We did not assess to what extent delayed nausea reflected conditioned nausea. and at present this must remain speculation.
We conclude that individual differences in delayed nausea after chemotherapy are influenced by neuroendocrine factors and linked both to the pituitary-adrenal cortical axis as indexed by cortisol (Fredrikson et al., 1992; Hursti et al., 1993) and to the sympathetic-adrenal medullary axis as reflected in noradrenaline. This may serve to tailor treatment strategies for patients likely to experience severe delayed emesis. It should support further study of neuroendocrine mechanisms involved in modulating chemotherapy emesis and particularly the possible role of the area postrema and the locus coeruleus and their interaction.
